These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714 [TBL] [Abstract][Full Text] [Related]
9. The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations. Choi SH; Shin I; Kim N; Nam Y; Sim T Biochem Biophys Res Commun; 2020 Nov; 532(2):315-320. PubMed ID: 32873393 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF Hong SP; Ahn SK Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859 [TBL] [Abstract][Full Text] [Related]
11. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251 [TBL] [Abstract][Full Text] [Related]
12. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
13. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Johannessen CM; Boehm JS; Kim SY; Thomas SR; Wardwell L; Johnson LA; Emery CM; Stransky N; Cogdill AP; Barretina J; Caponigro G; Hieronymus H; Murray RR; Salehi-Ashtiani K; Hill DE; Vidal M; Zhao JJ; Yang X; Alkan O; Kim S; Harris JL; Wilson CJ; Myer VE; Finan PM; Root DE; Roberts TM; Golub T; Flaherty KT; Dummer R; Weber BL; Sellers WR; Schlegel R; Wargo JA; Hahn WC; Garraway LA Nature; 2010 Dec; 468(7326):968-72. PubMed ID: 21107320 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495 [TBL] [Abstract][Full Text] [Related]
15. BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600Ε CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis. Koumaki K; Kontogianni G; Kosmidou V; Pahitsa F; Kritsi E; Zervou M; Chatziioannou A; Souliotis VL; Papadodima O; Pintzas A Biochim Biophys Acta Mol Basis Dis; 2021 Apr; 1867(4):166061. PubMed ID: 33385518 [TBL] [Abstract][Full Text] [Related]
16. Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463 [No Abstract] [Full Text] [Related]
17. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. Joshi M; Rice SJ; Liu X; Miller B; Belani CP PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985 [TBL] [Abstract][Full Text] [Related]
18. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965 [TBL] [Abstract][Full Text] [Related]
19. EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines. Kim SM; Kim H; Jang KW; Kim MH; Sohn J; Yun MR; Kang HN; Kang CW; Kim HR; Lim SM; Moon YW; Kim JH; Paik S; Cho BC Mol Cancer Ther; 2016 Jul; 15(7):1627-36. PubMed ID: 27196768 [TBL] [Abstract][Full Text] [Related]
20. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]